Literature DB >> 21320541

A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.

Danher Wang1, Andreas Suhrbier, Adam Penn-Nicholson, Jan Woraratanadharm, Joy Gardner, Min Luo, Thuy T Le, Itaru Anraku, Michael Sakalian, David Einfeld, John Y Dong.   

Abstract

Chikungunya virus, a mosquito-borne alphavirus, recently caused the largest epidemic ever seen for this virus. Chikungunya disease primarily manifests as a painful and debilitating arthralgia/arthritis, and no effective drug or vaccine is currently available. Here we describe a recombinant chikungunya virus vaccine comprising a non-replicating complex adenovirus vector encoding the structural polyprotein cassette of chikungunya virus. A single immunisation with this vaccine consistently induced high titres of anti-chikungunya virus antibodies that neutralised both an old Asian isolate and a Réunion Island isolate from the recent epidemic. The vaccine also completely protected mice against viraemia and arthritic disease caused by both virus isolates.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21320541      PMCID： PMC3061842          DOI： 10.1016/j.vaccine.2011.01.108

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  68 in total

1.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.

Authors:  Karine Labadie; Thibaut Larcher; Christophe Joubert; Abdelkrim Mannioui; Benoit Delache; Patricia Brochard; Lydie Guigand; Laurence Dubreil; Pierre Lebon; Bernard Verrier; Xavier de Lamballerie; Andreas Suhrbier; Yan Cherel; Roger Le Grand; Pierre Roques
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

2.  Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases.

Authors:  Sophie Larrieu; Nicolas Pouderoux; Thierry Pistone; Laurent Filleul; Marie-Catherine Receveur; Daouda Sissoko; Khaled Ezzedine; Denis Malvy
Journal:  J Clin Virol       Date:  2009-12-08       Impact factor: 3.168

Review 3.  Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.

Authors:  Sergey S Seregin; Andrea Amalfitano
Journal:  Expert Opin Biol Ther       Date:  2009-12       Impact factor: 4.388

4.  Chikungunya in Singapore: imported cases among travelers visiting friends and relatives.

Authors:  Poh Lian Lim; Helen May-Lin Oh; Eng Eong Ooi
Journal:  J Travel Med       Date:  2009 Jul-Aug       Impact factor: 8.490

5.  A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity.

Authors:  Wayne A Schroder; Thuy T T Le; Lee Major; Shayna Street; Joy Gardner; Eleanore Lambley; Kate Markey; Kelli P MacDonald; Richard J Fish; Ranjeny Thomas; Andreas Suhrbier
Journal:  J Immunol       Date:  2010-02-03       Impact factor: 5.422

6.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 7.  The immunobiology of viral arthritides.

Authors:  Andreas Suhrbier; Suresh Mahalingam
Journal:  Pharmacol Ther       Date:  2009-09-27       Impact factor: 12.310

8.  Clinical profile of chikungunya fever in patients in a tertiary care centre in Maharashtra, India.

Authors:  S D Suryawanshi; A H Dube; R K Khadse; S V Jalgaonkar; P S Sathe; S D Zawar; M P Holay
Journal:  Indian J Med Res       Date:  2009-04       Impact factor: 2.375

9.  Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes.

Authors:  Konstantin A Tsetsarkin; Charles E McGee; Sara M Volk; Dana L Vanlandingham; Scott C Weaver; Stephen Higgs
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

10.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226
View more
  51 in total

Review 1.  Chikungunya virus: evolution and genetic determinants of emergence.

Authors:  Konstantin A Tsetsarkin; Rubing Chen; Michael B Sherman; Scott C Weaver
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

2.  Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.

Authors:  Haiyan Chu; Subash C Das; Jeremy F Fuchs; M Suresh; Scott C Weaver; Dan T Stinchcomb; Charalambos D Partidos; Jorge E Osorio
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

3.  Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Kenneth Plante; Rodion Gorchakov; Robert L Seymour; Heather Vinet-Oliphant; Scott C Weaver
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

4.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 5.  Development of Vaccines for Chikungunya Fever.

Authors:  Jesse H Erasmus; Shannan L Rossi; Scott C Weaver
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

6.  Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.

Authors:  Adam D DeZure; Nina M Berkowitz; Barney S Graham; Julie E Ledgerwood
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 7.  51 years in of Chikungunya clinical vaccine development: A historical perspective.

Authors:  Arturo Reyes-Sandoval
Journal:  Hum Vaccin Immunother       Date:  2019-04-02       Impact factor: 3.452

8.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

9.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 10.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.